Dyadic International Inc (OQ:DYAI)

Business Focus: Biotechnology & Medical Research

Mar 28, 2024 04:00 pm ET
Dyadic Reports 2023 Full Year Results and Recent Company Progress
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in...
Mar 28, 2024 08:30 am ET
Dyadic Announces Change in Board and Management Leadership Roles
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in...
Mar 27, 2024 08:30 am ET
Dyadic to Attend Industry Events in April
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture...
Mar 26, 2024 08:30 am ET
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced the online publication of the manuscript "Filamentous...
Mar 21, 2024 08:30 am ET
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
Mar 14, 2024 04:30 pm ET
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building innovative microbial protein production platforms to address the growing demand for global protein...
Mar 11, 2024 09:57 am ET
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its...
Mar 11, 2024 08:30 am ET
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its...
Mar 01, 2024 08:30 am ET
Dyadic to Attend Industry Events in March
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
Feb 28, 2024 08:30 am ET
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global protein...
Feb 21, 2024 08:30 am ET
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for...
Feb 13, 2024 08:30 am ET
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq: MRVI), announced today a strategic partnership for the quantification of Host Cell Proteins (“HCP”) from the...
Feb 06, 2024 08:30 am ET
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global...
Feb 01, 2024 08:30 am ET
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
Jan 22, 2024 08:00 am ET
Dyadic International, Inc Invites You to Join Us at The Microcap Conference
Jupiter, Florida--(Newsfile Corp. - January 22, 2024) - Dyadic International, Inc (NASDAQ: DYAI), Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health., will be participating in The Microcap Conference, which will take place January 30, 31, February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.
Jan 02, 2024 08:30 am ET
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
Nov 30, 2023 08:30 am ET
Dyadic Attends Investor Events in December
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
Nov 29, 2023 08:30 am ET
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein...
Nov 20, 2023 08:30 am ET
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein...
Nov 08, 2023 04:00 pm ET
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet...
Oct 30, 2023 08:30 am ET
Dyadic to Present at Industry Events in November
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
Oct 25, 2023 04:30 pm ET
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet...
Oct 09, 2023 08:30 am ET
Dyadic Appoints Doug Pace to Its Executive Leadership Team
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet...
Oct 05, 2023 08:30 am ET
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet...
Sep 29, 2023 08:30 am ET
Dyadic to Present at Industry and Investor Events in October
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
Sep 26, 2023 08:30 am ET
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the...
Sep 19, 2023 08:00 am ET
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet...
Sep 12, 2023 04:30 pm ET
Dyadic to Present at BioProcess International
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
Aug 09, 2023 04:00 pm ET
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and produce biopharmaceuticals and alternative proteins for...
Aug 07, 2023 08:30 am ET
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and manufacture biopharmaceuticals and alternative proteins for...
Jul 26, 2023 04:30 pm ET
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet...
Jul 24, 2023 08:30 am ET
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein...
Jun 21, 2023 08:33 am ET
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet...
Jun 01, 2023 08:30 am ET
Dyadic to Participate at Upcoming Events in June
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
May 10, 2023 04:00 pm ET
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet...
May 10, 2023 08:30 am ET
Dyadic to Participate at Two Industry Events in May
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
May 08, 2023 08:30 am ET
Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet...
Apr 26, 2023 04:30 pm ET
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet...
Apr 18, 2023 08:30 am ET
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein...
Apr 12, 2023 08:00 am ET
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein...
Mar 30, 2023 08:30 am ET
Dyadic to Present at World Vaccine Congress Washington 2023
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
Mar 29, 2023 04:00 pm ET
Dyadic Reports 2022 Year End Results and Recent Company Progress
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet...
Mar 15, 2023 08:30 am ET
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet...
Mar 07, 2023 08:30 am ET
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein...
Mar 01, 2023 08:30 am ET
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
Feb 02, 2023 08:30 am ET
Dyadic to Participate in Two Upcoming Investor Conferences
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for...
Jan 24, 2023 08:30 am ET
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candi
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced that, in line with the timing announced...
Jan 19, 2023 08:30 am ET
Dyadic Announces Sale of Equity Interest in Alphazyme
Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for...
Jan 04, 2023 08:30 am ET
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for...
Dec 14, 2022 08:30 am ET
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), announced today that its study titled "Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85...
Nov 10, 2022 04:00 pm ET
Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet...
Nov 07, 2022 08:30 am ET
Dyadic to Present at Upcoming Industry and Investor Events in November
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for...
Oct 27, 2022 04:30 pm ET
Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet...
Oct 27, 2022 09:04 am ET
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet...
Oct 04, 2022 08:45 am ET
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for...
Sep 13, 2022 08:00 am ET
Dyadic Updates Market on Recent Scientific Achievements
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for...
Sep 08, 2022 08:30 am ET
Dyadic to Present at Upcoming Industry and Investor Events in September
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for...
Aug 10, 2022 04:00 pm ET
Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet...
Jul 27, 2022 04:30 pm ET
Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Jul 05, 2022 08:30 am ET
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary and patented microbial technologies to accelerate development, lower...
Jun 09, 2022 09:09 am ET
Dyadic to Participate in Three Upcoming Industry Events
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1 protein production platform to accelerate development, lower production...
Jun 02, 2022 09:27 am ET
Dyadic to Present at 2022 Jefferies Healthcare Conference
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower...
May 20, 2022 08:30 am ET
Dyadic to Present at H.C. Wainwright Global Investment Conference
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower...
May 12, 2022 04:00 pm ET
Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate...
May 11, 2022 08:30 am ET
Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary protein production platform, today announced that it has...
May 09, 2022 08:30 am ET
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and...
Apr 28, 2022 04:30 pm ET
Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Apr 13, 2022 08:52 am ET
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced today that Dyadic Licensee, Epygen Biotech PVD, LTD., has received funding from the Department of Biotechnology,...
Apr 04, 2022 08:30 am ET
Dyadic International to Present at Upcoming Scientific Medical Meetings
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower...
Mar 29, 2022 04:00 pm ET
Dyadic Reports 2021 Year End Results and Recent Company Progress
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Mar 15, 2022 04:30 pm ET
Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Feb 10, 2022 08:30 am ET
Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate...
Feb 07, 2022 08:30 am ET
Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower...
Jan 20, 2022 08:30 am ET
Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Dec 22, 2021 09:12 am ET
Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Dec 17, 2021 07:00 am ET
Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate...
Nov 10, 2021 04:00 pm ET
Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate...
Nov 09, 2021 08:30 am ET
Dyadic Appoints Chief Business Officer to Executive Leadership Team
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Oct 27, 2021 04:30 pm ET
Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Sep 10, 2021 08:30 am ET
Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate...
Aug 12, 2021 04:00 pm ET
Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
JUPITER, FL / ACCESSWIRE / August 12, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics today announced its financial results for the second quarter of 2021 and highlighted recent Company progress.
Aug 11, 2021 10:55 am ET
Thinking about buying stock in Dyadic Int, Seanergy Maritime, Cleveland-Cliffs, United States Steel, or Lightning Emotors?
NEW YORK, Aug. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DYAI, SHIP, CLF, X, and ZEV.
Aug 11, 2021 09:00 am ET
Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; “Sorrento”), a clinical stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, and Dyadic International, Inc. (NASDAQ: DYAI; “Dyadic”), a global biotechnology company...
Aug 11, 2021 08:35 am ET
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Jul 29, 2021 04:30 pm ET
Dyadic to Report Second Quarter 2021 Financial Results
JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended June 30, 2021 and host a corporate update confer
Jul 27, 2021 10:50 am ET
Thinking about buying stock in Tyme Technologies, New Oriental Education, Dyadic International, KE Holdings, or Iterum Therapeutics?
NEW YORK, July 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TYME, EDU, DYAI, BEKE, and ITRM.
Jul 27, 2021 08:20 am ET
Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Jun 28, 2021 08:30 am ET
Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and...
May 26, 2021 08:30 am ET
Dyadic announces development of COVID-19 Vaccine in India
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower...
May 24, 2021 08:30 am ET
Dyadic to Present at Upcoming Events
JUPITER, FL / ACCESSWIRE / May 24, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will participate in the following upcoming events:
May 13, 2021 04:00 pm ET
Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
JUPITER, FL / ACCESSWIRE / May 13, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics today announced its financial results for the first quarter of 2021 and highlighted recent Company progress.
May 03, 2021 08:30 am ET
Dyadic to Present at Upcoming Events
Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower...
Apr 29, 2021 04:00 pm ET
Dyadic to Report First Quarter 2021 Financial Results
JUPITER, FL / ACCESSWIRE / April 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended March 31, 2021 and host a corporate upda
Apr 22, 2021 08:30 am ET
Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges”
Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on developing and deploying its proprietary C1-cell protein production platform to optimize the development of...
Mar 30, 2021 04:00 pm ET
Dyadic Reports 2020 Year End Results and Recent Company Progress
JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs and other commercial products at flexible commercial scales, today announced its financial results for 2020 and recent business highlights.
Mar 29, 2021 08:30 am ET
UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Mar 29, 2021 07:00 am ET
CEO’s Presenting on the Emerging Growth Conference on March 31. Register now.
EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies announces the Schedule of the 4th Emerging Growth Conference....
Mar 22, 2021 08:30 am ET
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Mar 18, 2021 08:30 am ET
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Mar 16, 2021 04:00 pm ET
Dyadic to Report Fourth Quarter and Full Year 2020 Financial Results
JUPITER, FL / ACCESSWIRE / March 16, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for full year ended December 31, 2020 and host a corporate update conferenc
Mar 09, 2021 08:30 am ET
Dyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web Meeting
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate...
Feb 15, 2021 08:40 am ET
Dyadic to Present at Upcoming Events
JUPITER, FL / ACCESSWIRE / February 15, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company's management will be attending and presenting at the following upcoming investor and industry events:
Feb 03, 2021 08:30 am ET
Dyadic to Present at ZAPI Stakeholders Virtual Meeting
JUPITER, FL / ACCESSWIRE / February 3, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of vaccines, drugs and other biological products at flexible commercial scales, today announced that Ronen Tchelet, PhD, Dyadic's Chief Scientific Officer, will make a presentation during the European Union Innovative Medicines Initiative (IMI) Zoonotic Anticipation Prepare
Feb 02, 2021 09:00 am ET
Dyadic Enters Collaboration with TurtleTree Scientific to Develop Recombinant Protein Growth Factors
JUPITER, FL / ACCESSWIRE / February 2, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of vaccines, drugs and other biological products at flexible commercial scales, today announced a fully funded collaboration with TurtleTree Scientific to develop a number of recombinant protein growth factors which can be manufactured at high yields and at low cost in bioreactors
Jan 11, 2021 08:30 am ET
Dyadic International Appoints New Board Member
JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced the appointment of Patrick Lucy, to its Board of Directors, effective January 8, 2021. Mr. Lucy will serve as an independent director and a member of the Board's Science and Technology Committee. The size o
Dec 09, 2020 08:30 am ET
Dyadic to Interview with FOX Business Network on Wednesday December 9, 2020
JUPITER, FL / ACCESSWIRE / December 9, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb, has confirmed an interview with FOX Business Network for the following program today:
Nov 12, 2020 04:30 pm ET
Dyadic Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
JUPITER, FL / ACCESSWIRE / November 12, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended September 30, 2020, and recent developments.
Oct 29, 2020 04:30 pm ET
Dyadic to Report Third Quarter 2020 Financial Results on Thursday, November 12, 2020
JUPITER, FL / ACCESSWIRE / October 29, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended September 30, 2020 after the market close on Thursday, November 12, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss th
Oct 12, 2020 08:30 am ET
Dyadic Updates Market on COVID-19 Initiatives
JUPITER, FL / ACCESSWIRE / October 12, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today is updating the market on the progress made in certain of its coronavirus (COVID-19) programs globally.
Sep 22, 2020 06:30 pm ET
Sidoti Virtual Investor Conference
NEW YORK, NY / ACCESSWIRE / September 22, 2020 / Sidoti & Company, LLC has released the presentation schedule, with weblink click-throughs, for Wednesday, September 23, 2020, the first day of its two-day Fall 2020 Virtual Investor Conference. The presentation schedule and related links for day two of the virtual event, Thursday, September 24, 2020, will be published shortly after the conclusion of Wednesday's session or can be found at www.sidoticonference.com/events (click Schedule).
Sep 17, 2020 08:30 am ET
Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development
LIANYUNGANG, CHINA and JUPITER, FL / ACCESSWIRE / September 17, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced collaboration with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui") (SSE:600276) to apply Dyadic's C1 technology to the development of selected Hengrui biologic
Sep 14, 2020 08:30 am ET
Dyadic to Present at Upcoming Investor and Industry Events
JUPITER, FL / ACCESSWIRE / September 14, 2020 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company's management will be attending and presenting at the following investor and industry events in September:
Aug 31, 2020 05:00 pm ET
LD Micro -- 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 13, 2020 04:30 pm ET
Dyadic Announces Second Quarter 2020 Results and Highlights Recent Company Progress
JUPITER, FL / ACCESSWIRE / August 13, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended June 30, 2020, and recent developments.
Jul 30, 2020 04:00 pm ET
Dyadic to Report Second Quarter 2020 Financial Results on Thursday, August 13, 2020
JUPITER, FL / ACCESSWIRE / July 30, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended June 30, 2020 after the market close on Thursday, August 13, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those result
Jul 15, 2020 08:30 am ET
Dyadic International Announces Fully Funded Human Health R&D Collaboration with a Top Five Pharmaceutical Company
JUPITER, FL / ACCESSWIRE / July 15, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a new, fully-funded collaboration with another top five global pharmaceutical company.
Jul 08, 2020 08:30 am ET
Dyadic Announces Two New Fully Funded Collaborations with Leading Global Animal Health Companies
JUPITER, FL / ACCESSWIRE / July 8, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into new fully funded collaborations with two of the leading global animal health companies to demonstrate the C1
Jun 29, 2020 08:00 am ET
Dyadic Joins Russell 2000(R) Index and Russell 3000(R) Index
JUPITER, FL / ACCESSWIRE / June 29, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, announced today that the Company will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index effective after the US market opens on June 29, as a result of the annual Russell in
Jun 10, 2020 08:30 am ET
Dyadic and Frederick National Laboratory to Develop Cell Lines for COVID-19 Vaccine Candidates Using Dyadic's C1 Gene Expression Platform
JUPITER, FL / ACCESSWIRE / June 10, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that it was selected by the Frederick National Laboratory to engineer its patented and proprietary C1 cell lines to produce a number of COVID-19 vaccine candida
May 14, 2020 04:00 pm ET
Dyadic Reports 2020 First Quarter Results and Recent Developments
JUPITER, FL / ACCESSWIRE / May 14, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended March 31, 2020, and recent developments.
Apr 30, 2020 04:00 pm ET
Dyadic to Report First Quarter 2020 Financial Results on Thursday, May 14, 2020
JUPITER, FL / ACCESSWIRE / April 30, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended March 31, 2020 after the market close on Thursday, May 14, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to disc
Apr 20, 2020 08:00 am ET
Dyadic to Present and Participate in COVID-19 Panel at the Planet MicroCap Showcase Virtual Investor Conference 2020
JUPITER, FL / ACCESSWIRE / April 20, 2020 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will be presenting at the Planet MicroCap Showcase 2020 on Wednesday, April 22 at 12:40 PM Eastern Time. Mark Emalfarb, CEO of Dyadic, will be hosting the
Mar 30, 2020 04:00 pm ET
Dyadic Reports 2019 Year End Results and Recent Developments
JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the year ended December 31, 2019, and recent developments.
Mar 30, 2020 09:00 am ET
Dyadic Announces Nonexclusive Research License with WuXi Biologics
JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that it has entered into a nonexclusive research collaboration with WuXi Biologics, a leading global open-access biologics technology platform company and Cont
Mar 19, 2020 09:00 am ET
Dyadic International, Inc. to Present at the New York City based Investor Summit on March 25th-26th
NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Dyadic International, Inc. (Nasdaq: DYAI) Dyadic's Chief Financial Officer Ping Rawson will be presenting at this year's New York City based Investor Summit on March 25th-26th.
Mar 18, 2020 04:15 pm ET
Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress
JUPITER, FL / ACCESSWIRE / March 18, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its management participated in the ROTH Virtual Conference on Tuesday, March 17, 2020.
Mar 16, 2020 08:00 am ET
Dyadic to Report Year End 2019 Financial Results on Monday, March 30, 2020
JUPITER, FL / ACCESSWIRE / March 16, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for year ended December 31, 2019 after the market close on Monday, March 30, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss tho
Feb 25, 2020 10:15 am ET
Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases
NES-ZIONA, ISRAEL and JUPITER, FL / ACCESSWIRE / February 25, 2020 / Dyadic International, Inc. (''Dyadic'') (NASDAQ:DYAI), a global biotechnology company announced today that they are joining the global fight against the coronavirus outbreak by collaborating with The Israel Institute for Biological Research ("IIBR"), a governmental research institute established to provide the State of Israel with scientific response to chemical and biological threats.
Feb 24, 2020 08:30 am ET
Dyadic Announces New Milestone as G2 Human Like Glycosylation Reached
Further Extends Company's Biologic Market Opportunities
Feb 05, 2020 04:15 pm ET
Dyadic to Present at Two Upcoming Conferences
JUPITER, FL / ACCESSWIRE / February 5, 2020 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb, will be presenting at the following investor conferences:
Jan 31, 2020 08:00 am ET
Dyadic to Interview with Bloomberg TV on Friday, January 31, 2020
JUPITER, FL / ACCESSWIRE / January 31, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb, has confirmed an interview with Bloomberg TV for the following program:
Jan 28, 2020 09:50 am ET
Dyadic Interviewed with FOX Business Network
JUPITER, FL / ACCESSWIRE / January 28, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb, was interviewed by Liz Claman "The Claman Countdown" from FOX Business Networ
Jan 27, 2020 08:00 am ET
Dyadic to Interview with FOX Business Network on Monday, January 27, 2020
JUPITER, FL / ACCESSWIRE / January 27, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb, has confirmed an interview with FOX Business Network for the following program:
Jan 06, 2020 04:10 pm ET
Dyadic Reports Continued Positive Business Trends and Scientific Results in Fourth Quarter 2019
JUPITER, FL / ACCESSWIRE / January 6, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today provided an update on its recent business developments and scientific results in the fourth quarter of 2019.
Nov 25, 2019 08:00 am ET
Nov 13, 2019 04:00 pm ET
Dyadic Reports Third Quarter 2019 Results And Recent Developments
JUPITER, FL / ACCESSWIRE / November 13, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced its financial results for the quarter ended September 30, 2019, and recent developments.
Oct 30, 2019 04:30 pm ET
Dyadic to Report Third Quarter 2019 Financial Results on Wednesday November 13, 2019
JUPITER, FL / ACCESSWIRE / October 30, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its financial results for the quarter ended September 30, 2019 after the market close on Wednesday, November 13, 2019 and it will host a conferenc
Oct 28, 2019 08:00 am ET
Dyadic Announces New Collaboration with Leading Animal Health Company
JUPITER, FL / ACCESSWIRE / October 28, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global platform biotechnology company, announced today that it has entered into a fully funded collaboration with one of the leading animal health companies to demonstrate the C1 technology for expression and production of therapeutic proteins for companion and farm animal health diseases.
Oct 10, 2019 08:30 am ET
Dyadic to Attend Three Upcoming Investor Conferences in October
JUPITER, FL / ACCESSWIRE / October 10, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb will be attending and presenting at the following conferences:
Sep 04, 2019 08:00 am ET
Dyadic to Present at Janney Healthcare Conference
Date: Monday, September 9, 2019Presentation Time: 9:55 a.m. ETWebcast Dial-In: U.S. & Canada Toll-Free 888-223-4954Webcast Web Login: htt
Aug 21, 2019 04:00 pm ET
Dyadic to Present at Four Upcoming Investor Conferences in September
The RHK Disruptive Growth ConferenceDate: Wednesday, September 4, 2019 Presentation Time: 4:40 p.m. ET Location: ReedSmith - NYC
Aug 13, 2019 04:00 pm ET
Dyadic Reports Second Quarter 2019 Results and Recent Developments
JUPITER, FL / ACCESSWIRE / August 13, 2019 / Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced its financial results for the quarter ended June 30, 2019, and rec
Jul 30, 2019 04:00 pm ET
Dyadic to Report Second Quarter 2019 Financial Results on Tuesday August 13, 2019
Webcast Link: https://www.investornetwork.com/event/presentation/50926.
Jul 05, 2019 08:30 am ET
Dyadic Extends Research and Development Agreement with VTT
JUPITER, FLORIDA / ACCESSWIRE / July 5, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global platform biotechnology company, announced today that it has extended its research and development contract ("Contract") through June 2022 with VTT Technical Research Centre of Finland Ltd. ("VTT"), a world leading synthetic biology research and development organization.
Jul 02, 2019 08:40 am ET
Dyadic Joins Russell Microcap(R) Index
JUPITER, FL / ACCESSWIRE / July 2, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, announced today that the Company was added to the Russell Microcap® Index effective July 1, as a result of the annual Russell index reconstitution.
Jun 27, 2019 09:23 am ET
Dyadic Announces Appointment of Ping Rawson to CFO
JUPITER, FL / ACCESSWIRE / June 27, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, today announced the appointment of Ping Rawson to Chief Financial Officer, effective immediately. Ms. Rawson was previously the Chief Accounting Officer of Dyadic and joined the Company in 20
Jun 11, 2019 08:50 am ET
Dyadic to Ring the Nasdaq Closing Bell on June 17, 2019
JUPITER, FL / ACCESSWIRE / June 11, 2019 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scale today announced that its President and Chief Executive Officer, Mark Emalfarb, other members of the management team, and other guests will ring the Nasdaq closing bel
May 17, 2019 08:15 am ET
Dyadic to Present at the 20th Annual B. Riley FBR Investor Conference and Upcoming Industry Events
JUPITER, FL / ACCESSWIRE / May 17, 2019 / Dyadic International, Inc. (the ''Company'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb will attend and present at the following investor conference and industry events:
May 09, 2019 04:00 pm ET
Dyadic Reports First Quarter 2019 Financial Results and Recent Developments
JUPITER, FL / ACCESSWIRE / May 9, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced its financial results for the quarter ended March 31, 2019, and recent developments.
May 08, 2019 09:35 am ET
Dyadic and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products and Vaccines
PUNE, INDIA and JUPITER, FL / ACCESSWIRE / May 8, 2019 / Dyadic International, Inc. (''Dyadic'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, is pleased to announce a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (''Serum''), one of the world's largest vaccine manufacturers, to develop a
May 06, 2019 04:30 pm ET
Dyadic Announces Sub-Licensing Agreement with Alphazyme
JUPITER, FL / ACCESSWIRE / May 6, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products at flexible commercial scales, is pleased to announce a sub-licensing agreement entered into with Alphazyme LLC ("Alphazyme"), a biotech company focused on producing molecular biology enzymes addressing markets for
Apr 30, 2019 08:00 am ET
Dyadic Announces Sub-Licensing Agreement with Luina Bio
JUPITER, FL / ACCESSWIRE / April 30, 2019 / Dyadic International, Inc. (''Dyadic'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, is pleased to announce it has entered into a worldwide sub-licensing agreement with Australian based drug development and contract manufacturing organization, Luina Bio Pty Ltd (''Luina Bio''), for
Apr 25, 2019 04:30 pm ET
Dyadic to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
JUPITER, FL / ACCESSWIRE / April 25, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its financial results for quarter ended March 31, 2019 after the market close on Thursday, May 9, 2019 and it will host a conference call that day at 5:00
Apr 15, 2019 08:00 am ET
Dyadic Announces Uplisting to the Nasdaq Capital Market
JUPITER, FL / ACCESSWIRE / April 15, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, is pleased to announce that its common stock has been approved to list on The Nasdaq Capital Market.
Apr 08, 2019 08:35 am ET
OTC Company Investor Presentations Now Available for On-Demand Viewing
NEW YORK, April 8, 2019 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, announced that the presentations from the April 4th, 2019 conference are now available for on-demand viewing at VirtualInvestorConferences.com.
Apr 01, 2019 08:35 am ET
Dyadic International to Webcast, Live, at VirtualInvestorConferences.com April 4th
JUPITER, Fla., April 1, 2019 /PRNewswire/ -- Dyadic International, Inc. (the "Company") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb will present live at VirtualInvestorConferences.com on April 4th.
Mar 28, 2019 09:51 am ET
Live Investor Conference & Webinar April 4th
NEW YORK, March 28, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming Virtual lnvestor Conference, the leading proprietary investor conference series.  Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:15 AM ET, with the first live webcast at 9:30 AM ET, on Thursday, April 4th.
Mar 27, 2019 04:30 pm ET
Dyadic Reports 2018 Year End Results and Recent Developments
JUPITER, FL / ACCESSWIRE / March 27, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the year ended December 31, 2018, and recent developments.
Mar 25, 2019 08:50 am ET
Dyadic to Present at Three Upcoming Investor Conferences
JUPITER, FL / ACCESSWIRE / March 25, 2019 / Dyadic International, Inc. (the "Company") (OTCQX: DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb and Chief Accounting Officer, Ping Rawson will be presenting at the following three upcoming investor conferences:
Mar 13, 2019 04:30 pm ET
Dyadic to Report Year End 2018 Financial Results on Wednesday March 27, 2019
JUPITER, FL / ACCESSWIRE / March 13, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for year ended December 31, 2018 after the market close on Wednesday, March 27, 2019 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss
Feb 25, 2019 10:35 am ET
Dyadic to Present at Two Upcoming Investor Conferences
JUPITER, FL / ACCESSWIRE / February 25, 2019 / Dyadic International, Inc. (the ''Company'') (OTCQX: DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb, will be presenting at the following two upcoming investor conferences:
Feb 13, 2019 12:10 pm ET
Dyadic Announces Effectiveness of Form 10 Registration Statement and Application to NASDAQ
JUPITER, FL / ACCESSWIRE / February 13, 2019 / Dyadic International, Inc. (the "Company") (OTCQX: DYAI) today announced that the Securities and Exchange Commission (the "SEC") has declared the Company's Registration Statement on Form 10-12G (the "Form 10") effective as of February 12, 2019. As a result, the Company is now subject to the periodic and current reporting requirements of Section 13(a) of the Securities and Exchange Act of 1934.
Jan 24, 2019 01:15 pm ET
Dyadic International Named to 2019 OTCQX Best 50
JUPITER, FL / ACCESSWIRE / January 24, 2019 / Dyadic International, Inc. ("Dyadic" or "the Company") (OTCQX: DYAI) is pleased to announce it has been named to the 2019 OTCQX® Best 50, a ranking of top performing companies traded on the OTCQX Best Market last year.
Jan 22, 2019 10:00 am ET
Dyadic to Present at NobleCon XV
JUPITER, FL / ACCESSWIRE / January 22, 2019 / Dyadic International, Inc. (the ''Company'') (OTCQX: DYAI) today announced that its CEO, Mark Emalfarb will present at NobleConXV - Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Monday, January 28, 12:30 pm Eastern Standard Time.
Jan 15, 2019 08:40 am ET
Dyadic Announces the Filing of Replacement Form 10 Registration Statement with SEC
JUPITER, FL / ACCESSWIRE / January 15, 2019 / Dyadic International, Inc. (the "Company") ("OTCQX: DYAI) today announced that the Company has filed a replacement Registration Statement on Form 10-12G (the "Replacement Form 10") with the Securities and Exchange Commission (the "Commission").
Jan 02, 2019 06:05 pm ET
Dyadic Announces Update Regarding Initial Form 10 Registration Statement Filing with SEC
JUPITER, FL / ACCESSWIRE / January 2, 2019 / Due to the federal government shutdown, the Securities and Exchange Commission (the "Commission") has not completed its review of Dyadic International, Inc's. (OTCQX: DYAI) (the "Company") Registration Statement on Form 10-12G (File No. 000-55264), filed on November 5, 2018 (the "Registration Statement"). As a result, on January 2, 2019, the Company notified the Commission of its desire to prevent the Registration Statement from becoming effective prior to completion of the Commission's review. The Comp
Nov 07, 2018 04:30 pm ET
Dyadic International Reports Third Quarter 2018 Financial Results
JUPITER, FL / ACCESSWIRE / November 7, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, announced its financial results for the quarter and nine months ended September 30, 2018.
Nov 05, 2018 09:45 am ET
VTT and Dyadic International to Present Data on C1 Protein Platform at AAPS PharmSci 360 and PEGS Europe
Data Demonstrate C1 Can Be Developed Into a New-Generation Therapeutic Protein Production System
Nov 05, 2018 08:30 am ET
Dyadic Announces the Filing of Initial Form 10 Registration Statement with the SEC
JUPITER, FL / ACCESSWIRE / November 5, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that the Company has filed a Form 10 registration statement with the U.S. Securities and Exchange Commission ("SEC"), in order to register its common stock under the Securities Exchange Act of 1934, as amended.
Oct 24, 2018 04:30 pm ET
Dyadic to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018
JUPITER, FL / ACCESSWIRE / October 24, 2018 / Dyadic International, Inc. (''Dyadic'') (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will report its financial results for the quarter ended September 30, 2018 after the market close on Wednesday, November 7, 2018 and that it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results.
Oct 16, 2018 08:30 am ET
Dyadic Announces Analyst Coverage Initiated by Zacks Small-Cap Research
Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs...
Oct 01, 2018 10:00 am ET
Dyadic International to Present Thursday October 4, 2018 at 2:30 p.m. at the OTCQX(R) Virtual Investor Conference
JUPITER, FL / ACCESSWIRE / October 1, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, today announced that it will present Thursday October 4, 2018 at 2:30 p.m. at the OTCQX® Virtual Investor Conference featuring US-based issuers traded on the OTCQX Best Market.
Sep 17, 2018 04:18 pm ET
Dyadic International to Present at The MicroCap Conference on October 2nd in New York City at the Essex House
NEW YORK, NY / ACCESSWIRE / September 17, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, today announced that Ping W. Rawson, Chief Accounting Officer, will be presenting at this year's MicroCap Conference on Tuesday, October 2nd at 2:30 p.m. ET in New York City. Ms. Rawson will also be available to meet with investors at the conference.
Sep 07, 2018 11:18 am ET
Dyadic International Announces Research Collaboration with Sanofi-Aventis
Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs...
Aug 09, 2018 04:00 pm ET
Dyadic International Reports Second Quarter 2018 Financial Results and Extension of Stock Repurchase Program
Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs...
Jul 26, 2018 04:30 pm ET
Dyadic International to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at...
Jun 18, 2018 09:50 am ET
Dyadic International Improves Monoclonal Antibody (mAb) Productivity Utilizing C1 Gene Expression Platform to Manufacture Biologics
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at...
May 10, 2018 04:30 pm ET
Dyadic International Reports First Quarter 2018 Financial Results
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at...
Apr 25, 2018 04:30 pm ET
Dyadic International to Announce First Quarter 2018 Financial Results and Host Conference Call on Thursday May 10, 2018
JUPITER, Fla., April 25, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic...
Mar 27, 2018 04:30 pm ET
Dyadic International Announces 2017 Year End Results and Recent Developments
JUPITER, Fla., March 27, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying our proprietary C1 gene expression platform to help speed up the development and production of...
Mar 15, 2018 04:30 pm ET
Dyadic International Appoints Chief Accounting Officer
JUPITER, Fla., March 15, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), today announced that Chief Financial Officer Thomas L. Dubinski
 will be on a medical leave of absence, effectively immediately. In Mr. Dubinski’s absence, other executive officers...
Mar 13, 2018 04:30 pm ET
Dyadic International to Announce Year End 2017 Financial Results and Host Conference Call on Tuesday March 27, 2018
JUPITER, Fla., March 13, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic...
Mar 06, 2018 09:00 am ET
VIDEO: Dyadic International Inc., President, Chief Executive Officer and Director Mark A. Emalfarb and Chief Commercial Officer Matthew Jones Featured in OTCQX Video Series
NEW YORK, March 6, 2018 /PRNewswire/ -- Dyadic International, Inc. (OTCQX: DYAI) President, CEO and Director Mark A. Emalfarb, and Chief Commercial Officer Matthew S. Jones, were interviewed by OTC Markets Group (OTCQX: OTCM) in its prominent OTCQX® Video Series. The series features interviews with senior executives of OTCQX companies as they showcase their businesses and investment profiles.
Feb 27, 2018 08:30 am ET
Dyadic International, Inc. Announces Research and Development Collaboration with Mitsubishi Tanabe Pharma Corporation To Produce Two Target Proteins in C1
JUPITER, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic...
Feb 07, 2018 08:30 am ET
Dyadic International, Inc. Announces Research and Development Collaboration To Produce An Active Ingredient in C1
JUPITER, Fla., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic...
Jan 16, 2018 08:30 am ET
Dyadic International, Inc. Announces Research and Development Collaboration with the Israel Institute for Biological Research (IIBR) to Combat Emerging Diseases & Threats
JUPITER, Fla., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic...
Jan 03, 2018 12:08 pm ET
Dyadic International Appoints New Board Member
JUPITER, Fla., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on the development and large-scale manufacture of low cost, better performing biologic vaccines and drugs at flexible commercial scales, today...
Nov 09, 2017 04:30 pm ET
Dyadic International Reports Third Quarter 2017 Financial Results
JUPITER, Fla., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended September 30, 2017....
Nov 09, 2017 04:30 pm ET
Dyadic International Reports Third Quarter 2017 Financial Results
JUPITER, Fla., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic...
Oct 09, 2017 09:31 am ET
Dyadic International Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
Oct 09, 2017 09:31 am ET
Dyadic International Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
Sep 28, 2017 09:35 am ET
Dyadic International to Webcast, Live, at VirtualInvestorConferences.com October 5
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
Sep 28, 2017 09:35 am ET
Dyadic International to Webcast, Live, at VirtualInvestorConferences.com October 5
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
Sep 25, 2017 09:15 am ET
OTC Markets Group Announces Agenda for OTCQX Virtual Investor Conference on October 5
NEW YORK, Sept. 25, 2017 /CNW/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the agenda for its next OTCQX® Virtual Investor Conference on October 5, 2017 featuring U.S.-based companies traded on the OTCQX Best Market. 
Sep 25, 2017 09:15 am ET
OTC Markets Group Announces Agenda for OTCQX Virtual Investor Conference on October 5
NEW YORK, Sept. 25, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the agenda for its next OTCQX® Virtual Investor Conference on October 5, 2017 featuring U.S.-based companies traded on the OTCQX Best Market. 
Aug 16, 2017 04:30 pm ET
Dyadic Announces $5 Million Stock Repurchase Program
JUPITER, Fla., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (OTCQX:DYAI) (“Dyadic”) announced that its Board of Directors has authorized a new stock repurchase program, under which the Company may repurchase up to $5 million of its outstanding common stock....
Jul 27, 2017 04:30 pm ET
Dyadic International to Announce Second Quarter 2017 Financial Results and Host Conference Call on Thursday August 10, 2017
JUPITER, Fla., July 27, 2017 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter ended June 30, 2017 after the market close on Thursday, August 10, 2017 and that it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results....
Jul 10, 2017 08:30 am ET
Dyadic Announces an Important Multi-Year Research and Development Arrangement to Further Advance Its Proprietary C1 Technology
JUPITER, Fla., July 10, 2017 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), announced today that it has entered into a comprehensive series of research and development agreements, including a potential commercialization agreement, with Biotechnology Development for Industry (“BDI Holdings”), a Spanish biotech company, and its subsidiaries – VLP The Vaccines Company, S.L.U. (“VLPbio”), and Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (“BDI Pharma”) (collectively “BDI”). Dyadic expects to leverage the BDI team’s know-how in the development of next...
May 11, 2017 04:30 pm ET
Dyadic International Reports First Quarter 2017 Financial Results
JUPITER, Fla., May 11, 2017 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying the proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended March 31, 2017....
Apr 27, 2017 04:30 pm ET
Dyadic International to Announce First Quarter 2017 Financial Results and Host Conference Call on Thursday, May 11, 2017
JUPITER, Fla., April 27, 2017 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter ended March 31, 2017 after the market close on Thursday, May 11, 2017 and that it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.